According to Globenewswire, BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to technological innovation and healthcare, announced that its board of directors has officially approved the company's new Ethereum-focused financial strategy. The decision marks BGLC becoming the first Nasdaq-listed company to prioritize Ethereum as an exclusive strategic financial asset, and echoes the recent announcement that Ethereum was included in the U.S. "cryptocurrency strategic reserve."
At the same time, BGLC released an Ethereum strategy white paper detailing the rationale behind the company's decision and the broader significance of Ethereum as a financial infrastructure asset. The white paper delves into institutional adoption, staking capabilities, and upcoming protocol upgrades that solidify Ethereum's long-term value and usefulness to enterprises.
Nasdaq-listed company BioNexus Gene Lab announces adoption of Ethereum financial reserve strategy
2025-03-06 02:17:44
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
纳斯达克上市公司BioNexus Gene Lab宣布采用以太坊财务储备战略Next article：
Pyth Network DAO 投票成立 Pyth 社区委员会
